



# MEDIA RELEASE

**For immediate release**

Wednesday 7 July 2021

## **PPAHS Position Paper calls for improved lung testing technologies and clinical procedures**

An insightful Position Paper published by the Physician-Patient Alliance for Health & Safety (PPAHS) coinciding with the American Thoracic Society's annual conference [ATS 2021] recognizes the need for improved technologies and procedures to measure lung dynamics and function that can be safely sustained during pandemics.

This Position Paper is a response by the PPAHS to a survey showing a reluctance by physicians and healthcare professionals to refer patients for lung function testing during the COVID pandemic.

Survey findings reveal less than one quarter of respondents had commissioned or conducted lung function testing during the COVID pandemic, and that those tests tended to be limited to essential lung function testing related to transplants, monitoring side-effects of chemotherapy and assessing candidates for surgery.

Recognizing that avoiding or delaying testing has serious implications for patient health and exposure to malpractice claims against doctors, the PPAHS has teamed with 4DMedical and Professor Naresh Punjabi, Chief of Pulmonary Critical Care at the University of Miami, in calling for safer alternatives to traditional testing during COVID and incidence of airborne infectious diseases.

The utilization of innovative methodologies such as Dr Punjabi's use of 4DMedical's patented XV Technology is another focus area of the paper, and the basis for a live presentation and discussion session held during ATS 2021.

PPAHS Executive Director, Dr Michael Wong joined 4DMedical clinical affairs expert, Dr Jason Kirkness, and Dr Punjabi to present this session at ATS 2021, exploring alternatives to traditional PFT during pandemics – available for viewing at: <https://vimeo.com/547719248>

<ends>

## CONTACT

Clint Rodgers; Vice President Marketing and Communications: +61 422378131 / +61 428587350  
(24 hours)

## PRODUCT INFORMATION

<https://4dmedical.com/our-products/clinical/>

## BACKGROUNDER

4DMedical is a medical technology company transforming respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

Through its technology 4DMedical is providing clinicians with greater insights into diseases of the lung, 4DMedical is focusing on providing better information to doctors and patients about lung function.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, assisting in providing sensitive, early diagnosis, and to monitor changes over time. The company's Software-as-a-Service (SaaS)-enabled scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower and safer levels of radiation than traditional methods.

Better information means better decisions, and better outcomes.

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

**4dmedical.com**

Melbourne, Australia

Los Angeles, USA